Condition: Solid Tumor · Sponsor: Emory University
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.
This description comes directly from the study's public registry record.
Kathryn Sutton, MD · 404-785-1651 · Kathryn.Sutton@choa.org
Always discuss trial participation with your own doctor first.
| Aflac Cancer & Blood Disorders Centers | Atlanta, Georgia, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Texas Children's Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04469530